Pegaspargase
drugOn this page
Also known as OncasparPeg-asparaginasePegaspargasa
Summary
Pegaspargase (CHEMBL2108546) is an approved enzyme (ATC L01XX24); indicated across 15 conditions including neoplasm and acute lymphoblastic leukemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Enzyme
- ATC class: L01XX24
- Indications: 15 conditions
- Clinical trials: 136
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108546 |
| Name | Pegaspargase |
| Type | Enzyme |
| Max phase | 4 |
| ATC | L01XX24 |
Also known as: Oncaspar, Peg-asparaginase, Pegaspargasa, Pegaspargase, PEGASPARGASE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
15 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| acute lymphoblastic leukemia | 4 | MONDO:0004967 | EFO:0000220 |
| lymphoid leukemia | 4 | MONDO:0005402 | EFO:0004289 |
| B-cell acute lymphoblastic leukemia | 3 | MONDO:0004947 | EFO:0000094 |
| T-cell acute lymphoblastic leukemia | 3 | MONDO:0004963 | EFO:0000209 |
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| precursor T-cell acute lymphoblastic leukemia | 3 | MONDO:0020512 | EFO:1001830 |
| acute biphenotypic leukemia | 3 | MONDO:0020322 | MONDO:0019460 |
| nasal cavity and paranasal sinus lethal midline granuloma | 3 | MONDO:0006828 | MONDO:0019472 |
| acute myeloid leukemia | 2 | MONDO:0018874 | EFO:0000222 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 136.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 53 |
| PHASE3 | 39 |
| PHASE1 | 14 |
| PHASE1/PHASE2 | 11 |
| Not specified | 9 |
| PHASE2/PHASE3 | 6 |
| PHASE4 | 4 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03844360 | PHASE4 | RECRUITING | Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease |
| NCT00192673 | PHASE4 | UNKNOWN | Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses |
| NCT01501136 | PHASE4 | UNKNOWN | Treatment of Natural Killer/T Cell Lymphoma-I/II |
| NCT04999878 | PHASE4 | UNKNOWN | A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome. |
| NCT02003222 | PHASE3 | ACTIVE_NOT_RECRUITING | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia |
| NCT02101853 | PHASE3 | ACTIVE_NOT_RECRUITING | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia |
| NCT02112916 | PHASE3 | ACTIVE_NOT_RECRUITING | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma |
| NCT02716233 | PHASE3 | ACTIVE_NOT_RECRUITING | A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents |
| NCT03007147 | PHASE3 | ACTIVE_NOT_RECRUITING | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
| NCT03020030 | PHASE3 | ACTIVE_NOT_RECRUITING | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents |
| NCT03117751 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma |
| NCT03643276 | PHASE3 | RECRUITING | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 |
| NCT03914625 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia |
| NCT03959085 | PHASE3 | RECRUITING | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy |
| NCT04365036 | PHASE3 | RECRUITING | A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) |
| NCT05602194 | PHASE3 | ACTIVE_NOT_RECRUITING | Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma |
| NCT05700448 | PHASE3 | NOT_YET_RECRUITING | Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma |
| NCT06255795 | PHASE3 | NOT_YET_RECRUITING | The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma |
| NCT07072585 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) |
| NCT00002744 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia |
| NCT00002766 | PHASE3 | COMPLETED | Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma |
| NCT00002812 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia |
| NCT00002816 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia |
| NCT00003437 | PHASE3 | UNKNOWN | Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia |
| NCT00005585 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia |
| NCT00005596 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia |
| NCT00005945 | PHASE3 | COMPLETED | Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia |
| NCT00022737 | PHASE3 | COMPLETED | Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia |
| NCT00075725 | PHASE3 | COMPLETED | Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia |
| NCT00103285 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
| NCT00381680 | PHASE3 | COMPLETED | Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia |
| NCT00400946 | PHASE3 | COMPLETED | 05-001: Treatment of Acute Lymphoblastic Leukemia in Children |
| NCT00408005 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma |
| NCT00557193 | PHASE3 | COMPLETED | Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
| NCT00671034 | PHASE3 | COMPLETED | Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia |
| NCT00720109 | PHASE2/PHASE3 | COMPLETED | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
| NCT00967057 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia |
| NCT01190930 | PHASE3 | COMPLETED | Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma |
| NCT01228331 | PHASE2/PHASE3 | COMPLETED | Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL |
| NCT02085655 | PHASE3 | UNKNOWN | PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).